Executive Summary
SAVR-after-TAVR mortality has fallen from 13.1% to 3.5% over the last decade, and more than half of isolated TAVR-explant candidates now carry predicted mortality under 3% in the new STS risk model published in Annals of Thoracic Surgery. That reframes the lifetime-management calculus the ESC 2025 spent so much ink on — if surgical bailout after a failed TAVR is genuinely low-risk in selected patients, the durability anxiety around implanting TAVR in 65-year-olds loosens, but so does the argument that redo-TAVR is the only reasonable second act. Meanwhile Jenscare dosed its first US TTVR implants and CMS closes in on a national TAVR coverage decision — access is expanding on both ends of the treatment pathway, which complicates the case for restraint.
- STS validated a de novo SAVR-after-TAVR risk model (N=5,708) with AUC 0.82 for operative mortality; era-based improvement is now built into the model. Annals of Thoracic Surgery
- Edwards released 10-year Resilia tissue data heading into Wednesday's Q2 print, sharpening the durability narrative against TAVR bioprostheses. MPO
- A propensity-matched real-world TAVR cohort (N=3,586) found no mortality difference between general and non-general anesthesia at 1 year, but signaled higher HF events with GA (HR 1.44). J Clin Anesth
- An externally validated 5-indicator anatomic score (C-statistic 0.725) stratifies intraprocedural risk in bicuspid TAVI — 50% event rate in the high-risk tier of the validation cohort. MedRxiv preprint
- Handgrip strength emerged as the only independent frailty predictor of 1-year death/rehospitalization after TAVI (HR 0.93 per kg) in a single-center Japanese cohort (N=123). Cureus
What to watch: Edwards Q2 earnings on July 23 land against the CMS TAVR NCD decision and the Resilia 10-year drop — a rare alignment of durability data, reimbursement, and market signal in a single week.
Aortic Valve (TAVR/TAVI)
[NOTABLE] The lifetime-management math for TAVR shifted today, and it shifted toward the surgeons. The STS Adult Cardiac Surgery Database analysis of 5,708 SAVR-after-TAVR cases (7/2014–3/2025) reports operative mortality dropping from 13.1% to 3.5% over the study period, with 53.3% of potentially redo-TAVR-eligible isolated cases now classified as low predicted risk (<3%). Annals of Thoracic Surgery. The model discriminates well (AUC 0.82 mortality; 0.73 morbidity/mortality) and — critically — includes era as an interaction term, acknowledging that surgical explant technique has matured. ESC 2025 explicitly warned that THV explantation still carries 12–17% mortality; the STS registry data says that figure is now cohort- and era-dependent, and in selected isolated cases considerably lower. This does not settle the redo-TAVR vs. explant debate, but it undercuts the reflexive assumption that TAVR failure equals a prohibitive-risk second procedure. ACC/AHA 2020 recommends SAVR for patients under 65 on durability grounds; for patients aged 65–70 — the bracket where ESC 2025 and ACC/AHA diverge most sharply — this is the first surgical rebuttal to the durability-doesn't-matter argument with registry weight behind it.
Two supporting items. A TriNetX target-trial-emulation study (N=3,586 matched) showed no mortality difference between general and non-general anesthesia for TAVR through 1 year, with NGA associated with lower 30-day readmission and — nominally — lower HF events at 365 days (HR 1.44 for GA; retrospective, unmeasured confounding likely). J Clin Anesth. And handgrip strength independently predicted 1-year death or rehospitalization after TAVI (HR 0.93/kg, N=123, single-center Japanese cohort) — a reminder that when ESC 2025 elevated early TAVR to Class IIa on EARLY TAVR data, it did so in a population where frailty phenotype still drives who benefits. Cureus.
Mitral Valve (MitraClip, PASCAL, TMVR)
A methodologically important finding for anyone doing M-TEER planning. A retrospective TEE study (N=75) found 2D and 3D measurements of mitral leaflet lengths correlated only moderately (r=0.41–0.74), with coefficients of variation for the posterior scallops reaching 40–60%. J Cardiothorac Vasc Anesth. 3D MPR halved interobserver variability for A2 and P2 measurements. M-TEER eligibility and grasping strategy are decided on millimeters — leaflet length dictates whether a device can achieve durable coaptation without creating iatrogenic stenosis. If routine 2D imaging carries a coefficient of variation approaching 50% for P1 and P3, some proportion of "borderline anatomy" screen failures and procedural bailouts are imaging artifacts, not anatomy. The finding does not overturn any guideline — ACC/AHA 2020 (Class IIa) and ESC 2025 (Class I) both accept M-TEER for ventricular SMR in COAPT-like patients — but it argues for 3D MPR as the standard of care for procedural planning, particularly when the anatomic call is close. Single-institution, no gold-standard comparator (surgical measurement) available.
Tricuspid Valve (TriClip, TTVR)
Jenscare implanted its first patients in the US pivotal trial of its transcatheter tricuspid valve replacement system this week. MassDevice. At least three TTVR platforms now have active US pivotal programs alongside Edwards' EVOQUE (already approved on TRISCEND II) and Abbott's early-stage systems. ESC 2025 rated transcatheter tricuspid treatment Class IIa (LOE A) for symptomatic severe TR with prohibitive surgical risk; ACC/AHA 2020 did not address the space at all. The pace of enrollment is outrunning comparative-effectiveness data — TRISCEND II showed superior QoL but higher pacemaker (17%) and bleeding rates than repair. STS/ACC TVT Registry real-world data on 1,034 EVOQUE cases reported 3.1% 30-day mortality and 15.9% new CIED — closer to registry conditions but selection-biased. The surgical comparator remains isolated TV surgery, historically 8–20% mortality but improving with earlier referral per ESC 2025's expanded surgical indications (Class I for symptomatic severe primary TR). Until head-to-head data exist — and they won't for years — device choice will remain a mix of anatomy, operator preference, and industry access. That is the honest state of the field.
Surgical vs. Transcatheter Comparisons
The STS explant paper is the day's head-to-head story, and it's oblique: it doesn't compare TAVR to SAVR at index, but it materially changes the salvage math after TAVR failure. Paired with Edwards' 10-year Resilia tissue data from the surgical side, the durability conversation gets a two-front push this week. MPO. Ten-year Resilia data — assuming the release matches the framing — puts the surgical bioprosthesis benchmark at a follow-up window TAVR does not yet have. The recent JACC Cardiovasc Interv meta-analysis of low-risk TAVR vs. SAVR at 5 years showed a mortality advantage for TAVR (HR 0.80), but 5 years is not 10, and neither trial cohort was younger than 65. ESC 2025's decision to push TAVI as primary treatment at age ≥70 in tricuspid AV is defensible on 5-year data; extending that logic to 65-year-olds — where ACC/AHA 2020 still recommends SAVR — remains the field's live debate.
Preprint Highlights
A Chinese multicenter development cohort (N=793) and external validation cohort (N=134) produced a 5-variable anatomic risk score for intraprocedural complications in bicuspid TAVI. MedRxiv. Composite intraprocedural event rate rose from 3.1% in low-risk to 50% in high-risk categories in validation; C-statistic 0.725; OR 1.55 per point. Bicuspid TAVI remains guideline-limited — both ACC/AHA 2020 and ESC 2025 rate it Class IIb — because RCTs excluded these anatomies, and NOTION 2's BAV signal (HR 3.8 for events with TAVI vs. SAVR, P=0.07) has not been resolved. A validated anatomic score, if it holds in Western populations, is exactly what's needed to move BAV TAVI from case-by-case guesswork toward structured selection. Not yet peer-reviewed, and the validation cohort is small.
Regulatory & Policy
Medical societies are lining up to formally comment ahead of the CMS final decision on its TAVR National Coverage Determination proposal. Cardiovascular Business. The proposal addresses volume thresholds, Heart Team composition, and site requirements — the levers that determined the last decade of TAVR access. Loosening will accelerate community-hospital TAVR growth; tightening will consolidate volume at academic centers. Both directions carry clinical consequences the coverage document alone won't capture.
Industry & Market
Two device-industry signals converged today. Jenscare's first US TTVR implants formally open a third pivotal TTVR program in the US, adding to the EVOQUE post-approval and Abbott early-stage competitive set. IndexBox published its embolic protection systems market analysis — a category that has quietly become a required accessory line for TAVR programs even as PROTECTED TAVR failed to show a clinical stroke reduction. IndexBox. The persistence of embolic protection as a market category despite equivocal RCT data illustrates a durable pattern: adjacent technologies attach themselves to primary procedures and take years to be de-adopted, if ever.
Financial Analysis
Edwards reports Q2 on July 23, and the setup is unusually loaded. Yahoo Finance pegs consensus at EPS $0.74 on $1.70B revenue. The 10-year Resilia data drop days before earnings is not accidental — it positions the surgical bioprosthesis story alongside the SAPIEN franchise narrative in a market that has grown skeptical about single-modality growth. EW at $85 sits 12% below analyst consensus target ($99) and 12% above its 6-month low. The stock has traded sideways on structural demand concerns and pipeline questions; a Resilia durability win plus solid TAVR volumes would answer both. The bigger story is BSX at $43.77 — down 52% over six months. Whatever mitral/tricuspid enthusiasm carried BSX through 2024–2025 has fully unwound, even as its transcatheter portfolio arguably deepened. The market is pricing in that clinical adoption of secondary MR TEER and tricuspid interventions isn't materializing at 2023 penciled velocities, ESC Class I upgrade notwithstanding.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Price: $85.00, -0.85% on the day; 6-month change -0.16%; range $74.66–$96.29.
- Fundamentals: Market cap $48.9B; trailing P/E 46.2; forward P/E 25.3; beta 0.85; 52-week range $72.30–$96.29.
- Analyst view: Target $99.00 (range $84–$110, 25 analysts); consensus Buy.
- Earnings: July 23 — EPS est $0.74, revenue est $1.70B.
- Commentary: Resilia 10-year data drop days before earnings is designed to reset the durability narrative. TAVR volumes and the M-TEER/PASCAL and EVOQUE trajectories matter more than the EPS beat.
Medtronic (MDT)
- Price: $83.29, +0.11%; 6-month change -15.52%; range $72.65–$103.71.
- Fundamentals: Trailing P/E 22.3; forward P/E 13.0; beta 0.58; 52-week range $73.31–$106.33.
- Analyst view: Target $97.84 (range $78–$121, 25 analysts); consensus Buy.
- Earnings: September 1 — EPS est $1.39, revenue est $9.55B.
- Commentary: Evolut Low Risk long-term follow-up remains its central TAVR asset, but structural heart is a smaller share of the overall franchise story than for EW.
Abbott (ABT)
- Price: $101.66, +0.97%; 6-month change -14.66%; range $81.39–$120.86.
- Fundamentals: Trailing P/E 32.9; forward P/E 16.8; beta 0.61; 52-week range $81.97–$137.49.
- Analyst view: Target $118.33 (range $92–$135, 24 analysts); consensus Buy.
- Earnings: October 14 — EPS est $1.42, revenue est $13.00B.
- Commentary: MitraClip franchise faces PASCAL competitive pressure. Tricuspid pipeline (TriClip, plus early-stage TTVR) is the growth story; execution against Edwards' EVOQUE will define 2026–2027.
Boston Scientific (BSX)
- Price: $43.77, -0.59%; 6-month change -52.27%; range $42.20–$94.75.
- Fundamentals: Market cap $65.1B; trailing P/E 18.4; forward P/E 11.8; beta 0.58; 52-week range $42.20–$109.50.
- Analyst view: Target $72.43 (range $55–$106, 28 analysts); consensus Strong Buy.
- Earnings: July 29 — EPS est $0.83, revenue est $5.37B.
- Commentary: Down more than half over six months. Analyst consensus remains bullish, but the market is discounting the pace of structural heart adoption. Q2 print will be a referendum on whether the sell-off is thesis-broken or overshoot.
Anteris Technologies (AVR.AX)
- Price: A$11.55, -2.12%; 6-month change +19.20%; range $7.13–$15.47.
- Fundamentals: Market cap A$1.1B; forward P/E -5.3; beta 0.73; 52-week range $4.79–$15.47.
- Analyst view: Single-analyst target A$13.00.
- Commentary: DurAVR THV pivotal program advancement is the singular catalyst. Small-cap volatility, single-product concentration risk.
Market outlook: The large-cap structural heart names are trading on adoption velocity, not on clinical wins. EW's Resilia data and BSX's Q2 print in the next 10 days will together clarify whether the 2026 sell-off in the sector reflects a durable slowdown in transcatheter growth or a temporary re-rating. CMS's TAVR NCD decision sits on top of both.
Clinical Trial Updates
Aortic
- NCT07591922 — Intraoperative Music Therapy in TAVR Patients. Status: Recruiting; Phase: NA; Enrollment: 100; Sponsor: Rhode Island Hospital; Last updated 2026-07-20. Adjunctive non-pharmacologic intervention study; not landmark, but signals continued attention to the periprocedural experience side of TAVR care.
Looking Ahead
Edwards' Q2 print Wednesday, framed by Resilia 10-year data and the pending CMS TAVR coverage decision, sets the tone for the second half of 2026 in structural heart. Watch whether the STS SAVR-after-TAVR mortality data starts to inflect Heart Team discussions in the 65–70 age bracket — where ESC 2025 and ACC/AHA 2020 diverge most sharply, and where the durability question actually bites.